Cargando…

Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia

BACKGROUND: Liposome bupivacaine is a novel formulation of the local anesthetic bupivacaine, designed to provide prolonged postsurgical analgesia. This analysis examined pooled efficacy data as reflected in cumulative pain scores from 10 randomized, double-blind liposome bupivacaine clinical studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergese, Sergio D, Ramamoorthy, Sonia, Patou, Gary, Bramlett, Kenneth, Gorfine, Stephen R, Candiotti, Keith A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346068/
https://www.ncbi.nlm.nih.gov/pubmed/22570563
http://dx.doi.org/10.2147/JPR.S30861
_version_ 1782232187007926272
author Bergese, Sergio D
Ramamoorthy, Sonia
Patou, Gary
Bramlett, Kenneth
Gorfine, Stephen R
Candiotti, Keith A
author_facet Bergese, Sergio D
Ramamoorthy, Sonia
Patou, Gary
Bramlett, Kenneth
Gorfine, Stephen R
Candiotti, Keith A
author_sort Bergese, Sergio D
collection PubMed
description BACKGROUND: Liposome bupivacaine is a novel formulation of the local anesthetic bupivacaine, designed to provide prolonged postsurgical analgesia. This analysis examined pooled efficacy data as reflected in cumulative pain scores from 10 randomized, double-blind liposome bupivacaine clinical studies in which the study drug was administered via local wound infiltration. METHODS: A total of 823 patients were exposed to liposome bupivacaine in 10 local wound infiltration studies at doses ranging from 66 mg to 532 mg in five surgical settings; 446 patients received bupivacaine HCl (dose: 75–200 mg) and 190 received placebo. Efficacy measures were assessed through 72 hours after surgery. RESULTS: Overall, 45% of patients were male and 19% were ≥65 years of age. In the analysis of cumulative pain intensity scores through 72 hours, liposome bupivacaine was associated with lower pain scores than the comparator in 16 of 19 treatment arms assessed, achieving statistically significant differences compared with bupivacaine HCl (P < 0.05) in five of 17 treatment arms. These results were supported by results of other efficacy measures, including time to first use of opioid rescue medication, proportion of patients avoiding opioid rescue medication, total postsurgical consumption of opioid rescue medication, and patient/care provider satisfaction with postoperative analgesia. Local infiltration of liposome bupivacaine resulted in significant systemic plasma levels of bupivacaine, which could persist for 96 hours; systemic plasma levels of bupivacaine following administration of liposome bupivacaine were not correlated with local efficacy. Liposome bupivacaine and bupivacaine HCl were generally well tolerated. CONCLUSION: Based on this integrated analysis of multiple efficacy measures, liposome bupivacaine appears to be a potentially useful therapeutic option for prolonged reduction of postsurgical pain in soft tissue and orthopedic surgeries.
format Online
Article
Text
id pubmed-3346068
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-33460682012-05-08 Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia Bergese, Sergio D Ramamoorthy, Sonia Patou, Gary Bramlett, Kenneth Gorfine, Stephen R Candiotti, Keith A J Pain Res Review BACKGROUND: Liposome bupivacaine is a novel formulation of the local anesthetic bupivacaine, designed to provide prolonged postsurgical analgesia. This analysis examined pooled efficacy data as reflected in cumulative pain scores from 10 randomized, double-blind liposome bupivacaine clinical studies in which the study drug was administered via local wound infiltration. METHODS: A total of 823 patients were exposed to liposome bupivacaine in 10 local wound infiltration studies at doses ranging from 66 mg to 532 mg in five surgical settings; 446 patients received bupivacaine HCl (dose: 75–200 mg) and 190 received placebo. Efficacy measures were assessed through 72 hours after surgery. RESULTS: Overall, 45% of patients were male and 19% were ≥65 years of age. In the analysis of cumulative pain intensity scores through 72 hours, liposome bupivacaine was associated with lower pain scores than the comparator in 16 of 19 treatment arms assessed, achieving statistically significant differences compared with bupivacaine HCl (P < 0.05) in five of 17 treatment arms. These results were supported by results of other efficacy measures, including time to first use of opioid rescue medication, proportion of patients avoiding opioid rescue medication, total postsurgical consumption of opioid rescue medication, and patient/care provider satisfaction with postoperative analgesia. Local infiltration of liposome bupivacaine resulted in significant systemic plasma levels of bupivacaine, which could persist for 96 hours; systemic plasma levels of bupivacaine following administration of liposome bupivacaine were not correlated with local efficacy. Liposome bupivacaine and bupivacaine HCl were generally well tolerated. CONCLUSION: Based on this integrated analysis of multiple efficacy measures, liposome bupivacaine appears to be a potentially useful therapeutic option for prolonged reduction of postsurgical pain in soft tissue and orthopedic surgeries. Dove Medical Press 2012-05-01 /pmc/articles/PMC3346068/ /pubmed/22570563 http://dx.doi.org/10.2147/JPR.S30861 Text en © 2012 Bergese et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Bergese, Sergio D
Ramamoorthy, Sonia
Patou, Gary
Bramlett, Kenneth
Gorfine, Stephen R
Candiotti, Keith A
Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia
title Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia
title_full Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia
title_fullStr Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia
title_full_unstemmed Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia
title_short Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia
title_sort efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346068/
https://www.ncbi.nlm.nih.gov/pubmed/22570563
http://dx.doi.org/10.2147/JPR.S30861
work_keys_str_mv AT bergesesergiod efficacyprofileofliposomebupivacaineanovelformulationofbupivacaineforpostsurgicalanalgesia
AT ramamoorthysonia efficacyprofileofliposomebupivacaineanovelformulationofbupivacaineforpostsurgicalanalgesia
AT patougary efficacyprofileofliposomebupivacaineanovelformulationofbupivacaineforpostsurgicalanalgesia
AT bramlettkenneth efficacyprofileofliposomebupivacaineanovelformulationofbupivacaineforpostsurgicalanalgesia
AT gorfinestephenr efficacyprofileofliposomebupivacaineanovelformulationofbupivacaineforpostsurgicalanalgesia
AT candiottikeitha efficacyprofileofliposomebupivacaineanovelformulationofbupivacaineforpostsurgicalanalgesia